Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy (SUNRISE-FA 2)
|Aug 25 2026
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia (FORWARD-FA)
|Jul 16 2026
Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich’s Ataxia (PROVE-FA)
|Jun 25 2026
Effects of Aerobic Training on Friedreich’s Ataxia
|Sep 25 2025
A Study of SGT-212 Gene Therapy in Friedreich’s Ataxia (FALCON)
|May 13 2025
A Multiple Ascending Dose Study of DT-216P2 in Patients with Friedreich’s Ataxia
|May 3 2025
An Open Label Study of Nomlabofusp in Subjects With Friedreich’s Ataxia
|May 2 2025
Clinical Course of Disease in Participants With FA Cardiomyopathy (CLARITY-FA)
|May 1 2025
Phase 1 Clinical Trial of an Investigational Gene Therapy for Cardiac Disease Associated with Friedreich’s Ataxia – AAVrh.10hFXN
|Oct 30 2024
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich’s Ataxia Who Are Prescribed it by Their Own Doctors
|Aug 7 2024
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study (UNIFAI)
|Aug 6 2024
Neurobooth – Digital Phenotyping for Better Measures